Table 1 Demographic and clinical data of PD patients with the list of AEs
Characteristic | All patients (N = 224) | |
Sex | Female (%) | 95 (42.4) |
Male (%) | 129 (57.6) | |
Side of first symptoms | Left (%) | 88 (39.3) |
Both (%) | 20 (8.9) | |
Right (%) | 116 (51.8) | |
Tremor-predominant PD | No (%) | 41 (18.3) |
Yes (%) | 183 (81.7) | |
Ever being treated with DAsc | No (%) | 55 (25.0) |
Yes (%) | 165 (75.0) | |
Age at diagnosis | Median (25–75%), years | 62.2 (55.0–71.6) |
Disease duration | Median (25–75%), years | 7.6 (3.8–14.0) |
Levodopa treatment durationb | Median (25–75%), years | 6.1 (2.3–11.0) |
LED at enrolmentc, d | Median (25–75%), mg/day | 970 (600–1343.63) |
Adverse event | Number (%) of patients experiencing the adverse event | |
Motor fluctuations | 119 (53.1) | |
Dyskinesia | 98 (43.8) | |
EDS and sleep attacks | 79 (35.5) | |
Visual hallucinationsa | 57 (25.6) | |
Nausea/vomitinga | 66 (29.6) | |
Orthostatic hypotensiona | 84 (37.7) | |
Peripheral edemaa | 44 (19.7) | |
Impulse control disordersa | 32 (14.3) | |